Immuneering Corporation (NASDAQ:IMRX) Stock Has Consensus Target Price of $15.71

Immuneering Corporation (NASDAQ:IMRX) has earned a consensus rating of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $15.71.

IMRX has been the subject of a number of recent research reports. Chardan Capital upgraded shares of Immuneering to a “strong-buy” rating in a report on Monday, August 3rd. Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Needham & Company LLC increased their price objective on Immuneering from $11.00 to $18.00 and gave the company a “buy” rating in a report on Monday, July 20th. Cantor Fitzgerald initiated coverage on Immuneering in a research report on Wednesday, July 8th. They set an “overweight” rating and a $17.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating on shares of Immuneering in a research note on Thursday, August 27th.

Immuneering Stock Down 7.8%

Shares of NASDAQ:IMRX opened at $3.56 on Friday. The company has a market capitalization of $230.33 million, a price-to-earnings ratio of -3.42 and a beta of 0.46. Immuneering has a 52 week low of $3.55 and a 52 week high of $8.48. The firm has a 50 day moving average of $4.58 and a 200 day moving average of $4.83.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). On average, sell-side analysts expect that Immuneering will post -1.09 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of IMRX. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Immuneering in the fourth quarter worth $33,000. Integrated Wealth Concepts LLC purchased a new position in shares of Immuneering during the second quarter worth $34,000. Levin Capital Strategies L.P. acquired a new position in Immuneering during the first quarter valued at $53,000. Focus Financial Network Inc. purchased a new stake in Immuneering in the second quarter valued at $62,000. Finally, Cetera Investment Advisers acquired a new stake in Immuneering during the 1st quarter worth about $67,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation is a clinical-stage biopharmaceutical company focused on developing medicines for cancers driven by abnormal signaling through the RAS/MAPK pathway. The company applies computational biology and its Deep Cyclic Inhibition approach to design therapies intended to provide sustained pathway suppression while allowing normal cells periods of recovery.

Immuneering’s lead product candidate, IMM-1-104, is an oral therapy being developed for patients with RAS-mutated solid tumors, including pancreatic cancer.